公开(公告)号：US20220016188A1

公开(公告)日：2022-01-20

申请号：US17296072

申请日：2019-11-21

申请人： Board of Regents, The University of Texas System ,  Institut Gustave Roussy

发明人： Jennifer A. WARGO ,  Vancheswaran GOPALAKRISHNAN ,  Miles C. ANDREWS ,  Laurence ZITVOGEL ,  Valerio IEBBA

IPC分类号： A61K35/747 ,  A61K35/741 ,  A61K39/395 ,  A61P35/00 ,  C12Q1/689

摘要： Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and/or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides fmegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, or B7-2 inhibitor.

公开(公告)号：US20220056532A1

公开(公告)日：2022-02-24

申请号：US17279565

申请日：2019-09-27

申请人： INSTITUT GUSTAVE ROUSSY

发明人： Laurence ZITVOGEL ,  Valerio IEBBA

IPC分类号： C12Q1/6886 ,  C12Q1/689 ,  G06F17/18

摘要： The present invention relates to a method for in vitro determining if an individual having a renal cell cancer (RCC) is likely to respond to a treatment with an anti-PD1/PD-L1/PD-L2 Ab-based therapy, based on the analysis of the microbiota present in a stool sample from said individual. Twelve models useful to perform the above method are disclosed, as well as tools designed to easily perform this method.